New drug shows promise for teens with tough psoriasis

NCT ID NCT04718896

Completed Disease control Sponsor: UCB Biopharma SRL Source: ClinicalTrials.gov ↗

First seen May 21, 2026 · Last updated May 23, 2026 · Updated 1 time

Summary

This study looked at how the drug bimekizumab works in the bodies of teenagers aged 12 to 17 with moderate to severe plaque psoriasis. Researchers measured drug levels in the blood over time and tracked any side effects. The goal was to find the right dose and confirm the drug is safe for this age group.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Ps0020 40333

Wroclaw, Poland
Ps0020 40334

Wroclaw, Poland
Ps0020 40335

Warsaw, Poland
Ps0020 40396

Rzeszów, Poland
Ps0020 40625

Lodz, Poland
Ps0020 40626

Bialystok, Poland
Ps0020 40645

Frankfurt, Germany
Ps0020 50344

Indianapolis, Indiana, 46250, United States
Ps0020 50354

Calgary, Canada
Ps0020 50357

St. John's, Canada
Ps0020 50359

Cypress, Texas, 77433, United States

Conditions

Explore the condition pages connected to this study.

MODERATE TO SEVERE PLAQUE PSORIASIS